Scholar Rock Holding Corporation - Common Stock (SRRK)
27.94
-1.50 (-5.10%)
NASDAQ · Last Trade: Oct 18th, 9:50 PM EDT
Detailed Quote
Previous Close
29.44
Open
29.22
Bid
27.94
Ask
28.19
Day's Range
27.80 - 29.44
52 Week Range
22.71 - 46.98
Volume
4,953,779
Market Cap
2.65B
PE Ratio (TTM)
-9.568
EPS (TTM)
-2.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,726,006
Chart
About Scholar Rock Holding Corporation - Common Stock (SRRK)
Scholar Rock Holding Corp is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases, particularly those related to muscle and neuromuscular disorders. The company's proprietary approach leverages its knowledge of the biology underlying certain conditions to identify and target specific proteins that play a critical role in disease progression. By developing these targeted therapies, Scholar Rock aims to offer new, effective treatment options for patients who currently have limited alternatives. The company is dedicated to advancing its research and clinical programs while fostering collaboration within the scientific and medical communities. Read More
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the company granted inducement equity awards covering an aggregate of 114,500 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,429 shares of common stock and inducement restricted stock units, covering an aggregate of 49,071 shares of its common stock.
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) for the treatment of patients with spinal muscular atrophy (SMA). The CRL is related to observations identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility which was acquired by Novo Nordisk A/S in December 2024. The observations are not specific to apitegromab. The CRL did not cite any other approvability concerns, including apitegromab’s efficacy and safety data or the third-party drug substance manufacturer.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock.
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156320) were published in the peer-reviewed journal The Lancet Neurology. The data showed that children and adults with SMA had improved motor function with apitegromab—as measured by the gold-standard Hammersmith Functional Motor Scale Expanded (HFMSE)—and decreased motor function with placebo despite all participants receiving ongoing survival motor neuron (SMN)-targeted treatment.
